The director general of the Indian Council of Medical Research (ICMR) Dr Balram Bhargava said at a press conference on Wednesday that the country’s indigenous Covaxin’s “bench-to-bedside” journey took less than eight months demonstrating self-reliant India’s capabilities to fight Covid-19.
“The bench-to-bedside journey of completely indigenous Covid-19 vaccine (COVAXIN) in less than 8 months’ time showcases the immense strength of Atmanirbhar Bharat to fight the odds & stand tall in the global public health community,” Bhargava said at the press conference.
According to Stanford Medicine the phrase “bench-to-bedside” refers to the transfer of a laboratory conducted research to the clinic to create something beneficial for humankind. Pre-clinical trials conducted on animals and clinical trials conducted on humans are both integral parts of this process.
Bhargava also reiterated what he said at a webinar organized by the Kerala government in February, about the interim results of Covaxin’s ongoing clinical trial showing effective results against variants of Covid-19. He added that the recent results which have been evaluated by a data safety and monitoring board has found Covaxin to be well tolerated across an expansive range of age groups. The phase 3 clinical trial enrolled 25,800 participants, including 2,433 individuals over the age of 60 and 4,500 individuals with comorbidities.
– Hindustan Times